Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into tetrahydrofolate. This inhibition reduces the production of nucleotides needed for DNA synthesis, thereby slowing the proliferation of rapidly dividing cells in the immune system and in tumors.

The prescribed dose of Methotrexat Ebewe is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No universal dosing schedule is provided; the prescriber sets the regimen.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and embryotoxicity. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that can be taken orally and is generally less expensive. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for liver and blood‑cell effects than some newer biologics.

Methotrexat Ebewe should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas of high humidity or extreme heat.

Methotrexat Ebewe is taken orally, usually with a full glass of water. Depending on the prescribing physician’s instructions, it may be taken with or without food, and folic acid supplementation is often recommended to reduce mucosal side effects.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to anemia or infection, and acute renal failure. Patients should promptly report symptoms such as persistent nausea, shortness of breath, unusual bruising, or yellowing of the skin or eyes.

Methotrexat Ebewe is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for those with impaired renal function.